Cancer cells can modify their surface proteins, reducing the likelihood of being recognized by immune cells. For instance, they may downregulate MHC molecules that present antigens to T cells, effectively hiding from immune surveillance. Additionally, cancer cells can express proteins that inhibit immune cell activation, such as PD-L1, which binds to the PD-1 receptor on T cells, rendering them inactive.
